Nanobiotix Aktie
| 2,76EUR | -1,90EUR | -40,80% |
WKN DE: A1J7EB / ISIN: FR0011341205
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 90 | 100 | 102 | 102 | 108 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,29 | -0,11 |
Bilanz (in Mio. EUR) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 125 | 93 | 52 | 87 | 61 |
| Summe Anlagevermögen | 9 | 9 | 7 | 7 | 6 |
| Summe Aktiva | 134 | 102 | 60 | 94 | 67 |
Bilanz (in Mio. EUR) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 64 | 75 | 87 | 96 | 133 |
| Summe Eigenkapital | 70 | 27 | -27 | -2 | -66 |
| Summe Passiva | 134 | 102 | 60 | 94 | 67 |
Adresse
| 60, rue de Wattignies, 75012 Paris | |
| Telefon | +33 (1) 40-26-04-70 |
| Fax | +33 (1) 40-26-04-44 |
| Internet | http://www.nanobiotix.com |
Management
|
Alain Herrera
Member-Supervisory Board |
|
Anne-Juliette Hermant
Chief People Officer |
|
Anne-Marie Graffin
Deputy Chairman-Supervisory Board |
|
Bart van Rhijn
Chief Financial & Business Officer |
|
Craig West
Senior Vice President-Investor Relations |
|
Enno Spillner
Member-Supervisory Board |
|
Gary M. Phillips
Chairman-Supervisory Board |
|
Laurent Lévy
Chairman-Executive Board & Chief Executive Officer |
|
Louis Kayitalire
Chief Medical Officer |
|
Margaret Galluzzi
Vice President & Head-Global Clinical Operations |
|
Patrick Tricoli
Global Head-Business Development |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.